Veracyte (VCYT) Stock Forecast & Price Target

Compare

570 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VCYT Analyst Ratings

Moderate Buy

3 Buy

1 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Veracyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VCYT Stock 12 Month Forecast

Average Price Target

$47.25

▲(32.28% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $47.25 with a high forecast of $50.00 and a low forecast of $43.00. The average price target represents a 32.28% change from the last price of $35.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","51":"$51","29.25":"$29.3","36.5":"$36.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,29.25,36.5,43.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.16,39.07076923076923,39.981538461538456,40.89230769230769,41.80307692307692,42.71384615384615,43.62461538461538,44.535384615384615,45.44615384615385,46.356923076923074,47.26769230769231,48.178461538461534,49.08923076923077,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.16,38.85923076923076,39.558461538461536,40.2576923076923,40.956923076923076,41.65615384615384,42.355384615384615,43.05461538461538,43.753846153846155,44.45307692307692,45.152307692307694,45.85153846153846,46.550769230769234,{"y":47.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.16,38.53230769230769,38.90461538461538,39.276923076923076,39.64923076923077,40.02153846153846,40.393846153846155,40.76615384615384,41.138461538461534,41.51076923076923,41.88307692307692,42.255384615384614,42.62769230769231,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$47.25

Lowest Price Target$43.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Sarepta Therapeutics (NASDAQ: SRPT)

Michael Matson

Needham

$44→$48

Buy

34.38%

Upside

Reiterated

02/26/26

Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target

Kyle Mikson CFA

Canaccord Genuity

$43

Hold

20.38%

Upside

Reiterated

02/26/26

Canaccord Genuity Sticks to Its Hold Rating for Veracyte (VCYT)

Subbu Nambi

Guggenheim

$50

Buy

39.98%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Sarepta Therapeutics (NASDAQ: SRPT) and Viridian Therapeutics (NASDAQ: VRDN)

Kallum Titchmarsh

Morgan Stanley

$48

Sell

34.38%

Upside

Reiterated

01/11/26

Veracyte: Strong Near-Term Performance but Execution and Valuation Risks Justify Sell Rating

William Bonello

Craig-Hallum

$45

Buy

25.98%

Upside

Reiterated

11/06/25

Veracyte (VCYT) Gets a Buy from Craig-Hallum

Lu Li

UBS

$42→$48

Buy

34.38%

Upside

Reiterated

11/05/25

UBS Keeps Their Buy Rating on Veracyte (VCYT)

Keith Hinton

Freedom Capital Markets

$45

Buy

25.98%

Upside

Initiated

10/16/25

Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets

Puneet Souda

Leerink Partners

$45

Buy

25.98%

Upside

Reiterated

08/07/25

Veracyte's Strong Clinical Evidence and Market Growth Justify Buy Rating

Sung Ji Nam

Scotiabank

$44

Buy

23.18%

Upside

Reiterated

05/21/25

Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Sarepta Therapeutics (NASDAQ: SRPT)

Michael Matson

Needham

$44→$48

Buy

34.38%

Upside

Reiterated

02/26/26

Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target

Kyle Mikson CFA

Canaccord Genuity

$43

Hold

20.38%

Upside

Reiterated

02/26/26

Canaccord Genuity Sticks to Its Hold Rating for Veracyte (VCYT)

Subbu Nambi

Guggenheim

$50

Buy

39.98%

Upside

Reiterated

02/04/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), Sarepta Therapeutics (NASDAQ: SRPT) and Viridian Therapeutics (NASDAQ: VRDN)

Kallum Titchmarsh

Morgan Stanley

$48

Sell

34.38%

Upside

Reiterated

01/11/26

Veracyte: Strong Near-Term Performance but Execution and Valuation Risks Justify Sell Rating

William Bonello

Craig-Hallum

$45

Buy

25.98%

Upside

Reiterated

11/06/25

Veracyte (VCYT) Gets a Buy from Craig-Hallum

Lu Li

UBS

$42→$48

Buy

34.38%

Upside

Reiterated

11/05/25

UBS Keeps Their Buy Rating on Veracyte (VCYT)

Keith Hinton

Freedom Capital Markets

$45

Buy

25.98%

Upside

Initiated

10/16/25

Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets

Puneet Souda

Leerink Partners

$45

Buy

25.98%

Upside

Reiterated

08/07/25

Veracyte's Strong Clinical Evidence and Market Growth Justify Buy Rating

Sung Ji Nam

Scotiabank

$44

Buy

23.18%

Upside

Reiterated

05/21/25

Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Veracyte

3 Months

xxx

Success Rate

16/23 ratings generated profit

Average Return

+17.29%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +17.29% per trade.

1 Year

Puneet SoudaLeerink Partners

Success Rate

16/21 ratings generated profit

Average Return

+14.52%

a rating ―

Copying Puneet Souda's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +14.52% per trade.

2 Years

xxx

Success Rate

17/23 ratings generated profit

Average Return

+80.23%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +80.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VCYT Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VCYT has received 6 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. VCYT average Analyst price target in the past 3 months is 47.25.

Each month's total comprises the sum of three months' worth of ratings.

VCYT Financial Forecast

VCYT Earnings Forecast

Next quarter’s earnings estimate for VCYT is $0.34 with a range of $0.23 to $0.41. The previous quarter’s EPS was $0.53. VCYT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.

VCYT Sales Forecast

Next quarter’s sales forecast for VCYT is $130.53M with a range of $128.00M to $133.33M. The previous quarter’s sales results were $140.64M. VCYT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VCYT has Performed in-line its overall industry.

VCYT Stock Forecast FAQ

What is VCYT’s average 12-month price target, according to analysts?

Based on analyst ratings, Veracyte’s 12-month average price target is 47.25.

What is VCYT’s upside potential, based on the analysts’ average price target?

Veracyte has 32.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VCYT a Buy, Sell or Hold?

Veracyte has a consensus rating of Moderate Buy which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.

What is Veracyte’s price target?

The average price target for Veracyte is 47.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $43.00. The average price target represents 32.28% Increase from the current price of $35.72.

What do analysts say about Veracyte?

Veracyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of VCYT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Veracyte (VCYT) Stock Forecast & Price Target

VCYT Analyst Ratings

VCYT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Veracyte

VCYT Analyst Recommendation Trends

VCYT Financial Forecast

VCYT Earnings Forecast

VCYT Sales Forecast

VCYT Stock Forecast FAQ

Detailed List of Analyst Forecasts